Research interests
I used to study how bacteria successively colonized the terrestrial environment via genomic variations during my PhD and later fascinated by how those tiny bugs, after land colonization, established extensive interactions with different hosts including us humans.
My research now is mainly focused on the roles that our gut microbes play in different cardiometabolic diseases such as NAFLD, T2D, and heart failure, and how the underlying human-microbiota interactions might affect the associated therapeutic options. For example, we have previously reported that metformin-adapted microbial shifts could help boost the glucose-lowering effect of this drug (2017, Nature Medicine) and the rapid improvement of liver lipid metabolism in humans is partly associated with microbially derived folate upon low-carbs, high-protein, and high-fat diet intervention (2018, Cell Metabolism). Besides, I am interested in the evolutionary, phylogenetic, and pan-genomic analyses of representative gut microbes.
Education and Work Experience
2021-present, Fudan Microbiome Center, Human Phenome Institute, Fudan University;
2021-present, Huashan Hospital affiliated to Fudan University;
2015-2020, Sahlgrenska university hospital, University of Gothenburg, Sweden;
2012-2014, Beijing Institute of Genomics, Chinese Academy of Sciences;
2007-2012, James Watson Institute of Genome Sciences, Zhejiang University;
2002-2006, Department of Life Sciences, Shandong University of Technology;
吴浩，复旦大学人类表型组研究院、复旦微生物组中心，青年研究员，博士生导师；复旦大学附属华山医院代谢与减重外科双聘专家；入选上海市浦江人才、青年领军人才；国家海外高层次人才（青年）。兼任生物物理学会肠道菌群分会委员、代谢生物学分会青年委员；生物化学与分子生物学会代谢专业委员会委员；微生物学会微生物组专业委员会委员；人体健康科技促进会肠道微生态与肠菌移植专业委员会委员；中华预防医学会微生态分会委员。主要研究肠道菌与饮食互作对肥胖、非酒精性脂肪肝及糖尿病等代谢性疾病发生发展及防治的影响，以第一或通讯作者身份在Nature Medicine，Cell Metabolism，Cell Host & Microbe, Nature Communications，EMBO Molecular Medicine，The ISME J等杂志发表多篇学术论文。